# Meiji Seika Pharma

> Meiji Seika Pharma is a VC fund in Tokyo backing Biotechnology, Medical and Health Care. See 7 investments, check sizes, portfolio. Updated Sep 2026.

- Type: VC Fund
- Location: Tokyo, Japan
- Total investments: 7
- Last investment: Mar 2026
- Lead investor: 43%
- Last updated: Sep 2026
- Website: https://www.meiji-seika-pharma.co.jp/

Meiji Seika Pharma is a VC fund in Tokyo focused on Biotechnology and Medical. Meiji Seika Pharma engages in the manufacturing and sales of ethical pharmaceuticals, agricultural chemicals and veterinary drugs.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 86% |
| Medical | 5 | 71% |
| Health Care | 2 | 29% |
| Biopharma | 1 | 14% |
| Manufacturing | 1 | 14% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Corporate Round | 3 | 43% |
| Venture - Series Unknown | 2 | 29% |
| Seed | 1 | 14% |
| Series B | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 43% |
| Japan | 2 | 29% |
| China | 1 | 14% |
| France | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Centivax | Centivax is a healthcare-based agency that provides biotechnology, pharmaceutical, medical device manufacturing, and therapeutic services. | $37M | Venture - Series Unknown | Mar 30, 2026 |  |
| Lyric Bio | LYRIC BIO develops biomanufacturing platforms for human donor-sourced therapeutics. The company focuses initially on increasing availability of intravenous immunoglobulin, using bioreactors that incorporate high-resolution, laser-printed 3D tissues originating from research at Prellis Biologics. Its approach integrates cell culture systems, processdesign, and scalable hardware to expand throughput while maintaining product consistency. Capabilities include the design of bioreactor components, process monitoring, and quality controls aligned to plasma-derived medicines. The goal is to reduce supply shortages for essential immunoglobulin therapies and create a path to broader access for donor-based biologics. | $6.6M | Seed | Dec 02, 2025 |  |
| Osivax | ​Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medicalpractitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively. | $10.6M | Series B | Mar 04, 2025 |  |
| MPM BioImpact | MPM BioImpact is a biotechnology investment firm specializing in managing early-stage venture and private/public impact. | $20M | Corporate Round | Jan 10, 2025 |  |
| ARCALIS | ARCALIS specializes in manufacturing processes for messenger RNA pharmaceuticals. |  | Corporate Round | Nov 14, 2024 |  |
| Curadim Pharma | Curadim Pharma a pipeline-driven biotech company that discovers unutilized innovative drug seeds in Japan. | $12.4M | Venture - Series Unknown | Jun 04, 2016 |  |
| Solasia Pharma | Solasia Pharma is a pharmaceutical company focusing on oncology therapy and cancer care products. | $7.7M | Corporate Round | Jan 30, 2015 |  |

7 of 7 investments shown.

## Co-investors
- [Black Diamond Ventures](https://shizune.co/investors/profile/black-diamond-ventures) — VC Fund, 1 deal together
- [Draper Associates](https://shizune.co/investors/profile/draper-associates-2) — VC Fund, 1 deal together
- [Innovation Network Corporation of Japan](https://shizune.co/investors/profile/innovation-network-corp-of-japan) — VC Fund, 1 deal together
- [Kendall Capital Partners](https://shizune.co/investors/profile/kendall-capital-partners) — VC Fund, 1 deal together
- [Lucas Venture Group](https://shizune.co/investors/profile/lucas-venture-group) — VC Fund, 1 deal together
- [MBC Ventures](https://shizune.co/investors/profile/mbc-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Info Edge](https://shizune.co/investors/profile/info-edge) — VC Fund
- [Vector](https://shizune.co/investors/profile/vector-inc-) — VC Fund
- [Akatsuki Games Inc.](https://shizune.co/investors/profile/akatsuki-3) — VC Fund

## FAQ

### What does Meiji Seika Pharma invest in?

Meiji Seika Pharma invests primarily in Biotechnology, Medical and Health Care startups, most often at Corporate Round and Venture - Series Unknown stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Meiji Seika Pharma last invest?

The most recent investment recorded for Meiji Seika Pharma closed in Mar 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co